Taking on board higher near-term expenses
22/06/22 -"However, these expenses are investment into growth and should continue to support Astra’s sector-leading top-line growth in the coming years. Overall, our positive stock recommendation on the pharma ..."
Pages
67
Language
English
Published on
22/06/22
You may also be interested by these reports :
14/07/26
Pharmas’ AI investments pour broadly into two areas: Compute infrastructure, and AI models and platforms. Neither provides a long-term competitive ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...
06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...